ALLAY-LID-II

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

Thématique(s) / pathologie(s)

  • Maladie de Parkinson

Objectifs

Plus d'informations disponibles sur : https://clinicaltrials.gov/ct2/show/record/NCT02153632?term=osmotica&cond=Parkinson&rank=3

Promoteur

Adamas Pharmaceuticals, Inc.

Publication(s) scientifique(s)

  • Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord. 2022 Mar;96:65-73. 

    Publication ALLAY-LID-II

Statut

Recrutement clos

Centres participants

Partager

Mis à jour le 20 avril 2023